Valion Bio, Inc. (VBIO)
NASDAQ: VBIO · Real-Time Price · USD
0.1825
-0.0081 (-4.25%)
At close: Aug 17, 2026, 4:00 PM EDT
0.1825
0.00 (0.00%)
After-hours: Aug 17, 2026, 7:27 PM EDT
Valion Bio Revenue
Revenue (ttm)
$-86.00K
Revenue Growth
n/a
P/S Ratio
-6.71
Revenue / Employee
n/a
Employees
52
Market Cap
584.15K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.18M | -664.00K | -36.09% |
| Dec 31, 2022 | 1.84M | 583.00K | 46.38% |
| Dec 31, 2021 | 1.26M | 397.00K | 46.16% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jaguar Health | 29.57M |
| Scinai Immunotherapeutics | 1.21M |
| Decoy Therapeutics | 227.63K |
| VivoSim Labs | 112.00K |
| Biodexa Pharmaceuticals | 104.90K |
VBIO News
- 14 hours ago - Valion Bio announces U.S. government-funded entolimod studies - TheFly
- 16 hours ago - Valion Bio says Ukraine Ministry of Health accepts entolimod regulatory dossier - TheFly
- 3 days ago - Valion Bio Quarterly report: Q2 2026 - Filings
- 3 days ago - Valion Bio Transcript: EGM 2026 - Transcripts
- 4 days ago - Ukraine's Ministry Of Health Advances Entolimod Review Into Technical Assessment Phase - Accesswire
- 5 days ago - Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury - Accesswire
- 26 days ago - Valion Bio’s regulatory dossier for Entolimod accepted for review in Ukraine - TheFly
- 26 days ago - Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway - PRNewsWire